| Abstrakt: |
A report from the Universidad de Las Americas in Quito, Ecuador discusses the role of epigenetic modifications in cancer development and progression. These modifications, which involve changes in gene expression without altering the DNA sequence, have led to the development of a new class of therapeutic agents called epigenetic drugs. These drugs aim to modulate gene expression and alter the epigenetic landscape of cancer cells to curb cancer growth. Ongoing research and clinical trials are evaluating the efficacy of these drugs, particularly in combination with other treatments, to improve therapeutic outcomes and overcome drug resistance. The study highlights the importance of nutrition, inflammation control, and circadian rhythm regulation in modulating drug responses and influencing patient outcomes. Epigenetic drugs offer a more precise and targeted approach to cancer treatment with potentially fewer side effects compared to traditional chemotherapy, and they have the potential to optimize treatment strategies based on the unique epigenetic profiles of individual tumors. [Extracted from the article] |
